- The choice of first-line biological treatment in peripheral forms (anti-TNF, anti-IL17, anti-IL23, generally anti-TNF) must take into account the form of SpA (PsA), the presence or absence of uveitis or IBD, patient’s profile, and the decision must be shared between the patient and the physician. This evidence concerns the gene IL17A and uveitis.